PADI3 Antibody

Introduction to PADI3 Antibody

PADI3 antibody refers to immunological reagents specifically designed to detect and quantify the peptidylarginine deiminase type III (PADI3) enzyme. PADI3 is a calcium-dependent enzyme that converts arginine residues in proteins to citrulline, playing critical roles in epidermal differentiation, hair follicle development, and tumor biology . These antibodies are essential tools in research for studying PADI3’s function in diseases like uncombable hair syndrome, colorectal cancer, and breast cancer resistance .

Research and Diagnostic Use

PADI3 antibodies enable:

• Western blot (WB): Detection of PADI3 protein expression levels in cell lysates .

• Immunoprecipitation (IP): Isolation of PADI3 for downstream analysis .

• Immunohistochemistry (IHC): Localization of PADI3 in tissue sections .

• ELISA: Quantification of PADI3 in biological samples .

Key Research Findings

Antitumor Activity

PADI3 antibodies have revealed its dual role in cancer:

• Tumor Suppression:

  • Sirt2 Inhibition: PADI3 downregulates Sirt2, reducing AKT phosphorylation and promoting p21-mediated cell cycle arrest .

  • Hsp90/CKS1 Pathway: PADI3 suppresses Hsp90, leading to CKS1 inhibition and G1-phase arrest in colorectal cancer .

• Oncogenic Role:

  • Neratinib Resistance: Overexpression of PADI3 in HER2+ breast cancer cells reduces sensitivity to neratinib, a tyrosine kinase inhibitor .

Biomarker Potential

• Uncombable Hair Syndrome: PADI3 antibodies aid in diagnosing mutations linked to hair shaft deformities .

• Cancer Prognosis: Low PADI3 expression in colon cancer tissues correlates with aggressive tumor behavior, suggesting its use as a prognostic marker .

Therapeutic Targeting

• Combination Therapies: Inhibiting PADI3 may restore sensitivity to neratinib in breast cancer .

• Sirt2/CKS1 Inhibition: Targeting PADI3-Sirt2/CKS1 pathways offers novel strategies for colorectal cancer treatment .